SymBio Pharmaceuticals Limited (TSE: 4582) told the Tokyo Stock Exchange on September 24 that it has signed an exclusive, worldwide license agreement covering technology to develop brincidofovir, known as BCV, as a treatment and preventive drug for multiple sclerosis. The company describes the deal as a licensing agreement contracted through the US National Institutes of Health's National Institute of Neurological Disorders and Stroke, but names the US Department of Health and Human Services as the actual party to the patent license itself.
The agreement builds on a joint research pact SymBio signed with the neurological institute in March 2023, later extended by three years in March 2026 as the programme heads toward clinical testing. That collaboration produced a paper in the Journal of Clinical Investigation (2026;136(2):e19576) reporting that BCV selectively suppresses Epstein-Barr virus-positive cells, even at low concentrations. SymBio says its goal is a treatment that targets only virus-infected B cells while leaving virus-negative B cells intact, an approach it frames as a narrower alternative to existing anti-CD20 antibody therapies, which clear B cells indiscriminately.
The development stage matters here. SymBio says it is currently running animal studies in monkeys, work that sits well before any human clinical trial. SymBio's president and CEO, Yoshida, said in the release that the company will pursue a new treatment approach that directly targets the Epstein-Barr virus, citing viral reactivation as a principal risk factor in multiple sclerosis, a disease affecting an estimated three million people worldwide.
SymBio disclosed no financial terms, such as upfront payments, milestones or royalty rates, for the license. The company also said the agreement has no effect on its consolidated earnings forecast for the year ending December 2026. What the filing establishes is a licensing step and a research status, not a clinical result or a regulatory filing with any drug authority.